pbs_code
stringlengths 5
6
| drug
stringclasses 17
values | brand
stringclasses 30
values | formulation
stringclasses 37
values | indication
stringclasses 8
values | treatment_phase
stringclasses 57
values | streamlined_code
stringclasses 33
values | online_application
bool 2
classes | authority_method
stringclasses 2
values | hospital_type
stringclasses 3
values | schedule_code
int64 3.53k
3.53k
| schedule_year
int64 2.03k
2.03k
| schedule_month
stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
13301C | tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment | 14104 | true | STREAMLINED | Any | 3,531 | 2,025 | JANUARY |
12792G | tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab) | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
13069W | infliximab | Remsima SC | Solution for injection 120 mg in 1 mL pre-filled syringe | ankylosing spondylitis | Continuing treatment with subcutaneous form or switching from intravenous form to subcutaneous form | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
10895K | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | psoriatic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
10895K | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12768B | tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab) | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
10897M | certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
4284L | infliximab | Remicade | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Continuing treatment | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
4284L | infliximab | Remicade | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
3436W | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | ankylosing spondylitis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
3436W | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11323Y | certolizumab pegol | Cimzia | Solution for injection 200 mg in 1 mL pre-filled pen | psoriatic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11323Y | certolizumab pegol | Cimzia | Solution for injection 200 mg in 1 mL pre-filled pen | psoriatic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11323Y | certolizumab pegol | Cimzia | Solution for injection 200 mg in 1 mL pre-filled pen | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
10137M | certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | ankylosing spondylitis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
10137M | certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
13703F | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | First continuing treatment | 14567 | true | STREAMLINED | Any | 3,531 | 2,025 | JANUARY |
13703F | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | First continuing treatment | 14567 | true | STREAMLINED | Any | 3,531 | 2,025 | JANUARY |
13703F | adalimumab | Hyrimoz | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | First continuing treatment | 14567 | true | STREAMLINED | Any | 3,531 | 2,025 | JANUARY |
13703F | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | First continuing treatment | 14567 | true | STREAMLINED | Any | 3,531 | 2,025 | JANUARY |
12368Y | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment | 14107 | true | STREAMLINED | Private | 3,531 | 2,025 | JANUARY |
12368Y | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment | 14107 | true | STREAMLINED | Private | 3,531 | 2,025 | JANUARY |
12368Y | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment | 14107 | true | STREAMLINED | Private | 3,531 | 2,025 | JANUARY |
12368Y | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment | 14107 | true | STREAMLINED | Private | 3,531 | 2,025 | JANUARY |
10899P | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | psoriatic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
10899P | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12390D | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12390D | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12390D | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12390D | adalimumab | Hyrimoz | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12390D | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12390D | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12390D | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12390D | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12390D | adalimumab | Hyrimoz | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12390D | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12775J | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | rheumatoid arthritis | Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab) | null | true | AUTHORITY_REQUIRED | Public | 3,531 | 2,025 | JANUARY |
11565Q | tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11565Q | tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11565Q | tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11565Q | tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
13338B | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Continuing treatment | 14082 | true | STREAMLINED | Private | 3,531 | 2,025 | JANUARY |
9087G | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | psoriatic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
9087G | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | psoriatic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
9087G | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
9087G | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
9087G | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | psoriatic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
9087G | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | psoriatic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
9087G | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | psoriatic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
9087G | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | psoriatic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11376R | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled pen | ankylosing spondylitis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11376R | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled pen | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
9460X | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
9460X | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
9460X | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
9460X | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11318Q | certolizumab pegol | Cimzia | Solution for injection 200 mg in 1 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11560K | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | non-radiographic axial spondyloarthritis | Initial treatment - Initial 2 (Change or re-commencement of treatment after a break of less than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11560K | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | non-radiographic axial spondyloarthritis | Initial 1 (New patient), Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11560K | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | non-radiographic axial spondyloarthritis | Initial treatment - Initial 1 (New patient) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11560K | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | non-radiographic axial spondyloarthritis | Initial treatment - Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12084B | tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Continuing treatment in a patient weighing at least 30 kg | 14088 | true | STREAMLINED | Any | 3,531 | 2,025 | JANUARY |
8779C | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | ankylosing spondylitis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
8779C | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
5605B | abatacept | Orencia | Powder for I.V. infusion 250 mg | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,531 | 2,025 | JANUARY |
5605B | abatacept | Orencia | Powder for I.V. infusion 250 mg | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 3,531 | 2,025 | JANUARY |
5605B | abatacept | Orencia | Powder for I.V. infusion 250 mg | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 3,531 | 2,025 | JANUARY |
5605B | abatacept | Orencia | Powder for I.V. infusion 250 mg | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Public | 3,531 | 2,025 | JANUARY |
5605B | abatacept | Orencia | Powder for I.V. infusion 250 mg | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 3,531 | 2,025 | JANUARY |
5605B | abatacept | Orencia | Powder for I.V. infusion 250 mg | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,531 | 2,025 | JANUARY |
10896L | certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | psoriatic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12083Y | tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months in a patient weighing at least 30 kg) | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12083Y | tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break of more than 12 months in a patient weighing at least 30 kg) | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12083Y | tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient weighing at least 30 kg) | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
13686H | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | First continuing treatment | 14567 | true | STREAMLINED | Any | 3,531 | 2,025 | JANUARY |
13686H | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | First continuing treatment | 14567 | true | STREAMLINED | Any | 3,531 | 2,025 | JANUARY |
13686H | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | First continuing treatment | 14567 | true | STREAMLINED | Any | 3,531 | 2,025 | JANUARY |
13686H | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | First continuing treatment | 14567 | true | STREAMLINED | Any | 3,531 | 2,025 | JANUARY |
10071C | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,531 | 2,025 | JANUARY |
10071C | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Private | 3,531 | 2,025 | JANUARY |
10071C | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Private | 3,531 | 2,025 | JANUARY |
10071C | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Private | 3,531 | 2,025 | JANUARY |
10071C | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 3,531 | 2,025 | JANUARY |
10071C | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Continuing Treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,531 | 2,025 | JANUARY |
13699B | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | rheumatoid arthritis | Subsequent continuing treatment | 14604 | true | STREAMLINED | Any | 3,531 | 2,025 | JANUARY |
9456Q | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | ankylosing spondylitis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
9456Q | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | ankylosing spondylitis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
9456Q | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
9456Q | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
13715W | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | rheumatoid arthritis | Subsequent continuing treatment | 14621 | true | STREAMLINED | Public | 3,531 | 2,025 | JANUARY |
11748H | tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11748H | tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11748H | tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11748H | tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
3432P | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
3432P | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | psoriatic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
14286X | adalimumab | Abrilada | Injection 20 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment | 14136 | true | STREAMLINED | Public | 3,531 | 2,025 | JANUARY |
12442W | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12442W | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12442W | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
End of preview. Expand
in Dataset Viewer.
README.md exists but content is empty.
- Downloads last month
- 47
Size of downloaded dataset files:
24 kB
Size of the auto-converted Parquet files:
24 kB
Number of rows:
1,713